A 23andMe saliva assortment equipment is proven on March 25, 2025, in Oakland, Calif.
Barbara Ortutay/AP
cover caption
toggle caption
Barbara Ortutay/AP
PORTLAND, Ore. — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in chapter courtroom looking for to dam the sale of non-public genetic knowledge by 23andMe with out buyer consent. The lawsuit comes as a biotechnology firm seeks the courtroom’s approval to purchase the struggling agency.
Organic samples, DNA knowledge, health-related traits and medical data are too delicate to be bought with out every particular person’s specific, knowledgeable consent, Oregon Lawyer Basic Dan Rayfield stated in a information launch concerning the lawsuit. Clients ought to have the proper to regulate such deeply private info and it can’t be bought like atypical property, it stated.
23andMe clients use saliva-based DNA testing kits to study their ancestry and discover long-lost family. Based in 2006, the corporate additionally performed well being analysis and drug growth. However it struggled to discover a worthwhile enterprise mannequin since going public in 2021. In March it laid off 40% of its workers and filed for Chapter 11 chapter safety within the Jap District of Missouri, elevating issues concerning the security of buyer knowledge.
Regeneron Prescribed drugs stated final month it aimed to purchase the corporate for $256 million. Regeneron stated it will adjust to 23andMe’s privateness insurance policies and relevant legislation. It stated it will course of all buyer private knowledge in accordance with the consents, privateness insurance policies and statements, phrases of service, and notices at present in impact and have safety controls in place designed to guard such knowledge.
A court-appointed, unbiased shopper privateness ombudsman was resulting from study the proposed sale and the way it would possibly have an effect on shopper privateness and report back to the courtroom by Tuesday.
